| This week's sponsor is Premier Research. | | | Overcoming Risk in Oncology Drug Development
Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Click here for tips on finding the fast track. Premier Research. Built for biotech. |
Today's Rundown Novartis licenses out early antiviral work to Gilead J&J, Novartis help Medicxi raise €400M biopharma fund Mallinckrodt strikes $20M RNAi pact with Silence Therapeutics How a faulty gene that drives muscular dystrophy also shields cancer cells from immunotherapy EuroBiotech Report—Gilead-Galapagos, Alzheimer's fail, AM-Pharma and Abivax FiercePharmaAsia—Takeda’s €1.5B drug sale; Indian drugmakers in China; Eisai’s Alzheimer’s test Chutes & Ladders—Gilead CEO continues top-level revamp with 3 more exec exits Featured Story | | | Friday, July 19, 2019 Just two days after announcing its R&D chief was stepping down, Gilead Sciences has announced it will be buying up a few of Novartis’ unwanted early-stage infection assets. |
|
|
Top Stories Thursday, July 18, 2019 Medicxi has raised a €400 million ($448 million) biopharma investment fund. Johnson & Johnson and Novartis pumped money into the fund as cornerstone strategic investors, helping Medicxi wrap up fundraising in record time. Friday, July 19, 2019 Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at the complement cascade, a group of proteins that help antibodies and other immune cells fight off pathogens, and that play a part in promoting inflammation. Friday, July 19, 2019 A team at the Fred Hutchinson Cancer Research Center has discovered that the mechanisms that activate the normally silenced gene DUX4 in a type of muscular dystrophy also help some cancer cells evade immune checkpoint inhibitors. Thursday, July 18, 2019 In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million. Friday, July 19, 2019 Takeda scouts buyers for some Western European drugs worth €1.5 billion. Top Indian drugmakers— including Cipla, Sun Pharma, Aurobindo and Dr. Reddy's—expand in China. Eisai moves ahead with a quick Alzheimer's blood test. And more. Friday, July 19, 2019 Gilead CEO continues top-level revamp with three more exec exits; GSK snares ex-Novartis, AZ CFO as chairman; and Immusoft names former Amgen biologics head as CSO. Those moves plus more hirings, firings and retirings throughout the industry. | This week's sponsor is Medrio. | | | [Webinar] Accelerating Site and Patient Enrollment for Phase 1 Trials
Tuesday, July 23 | 2pm ET / 11am PT
This Fierce webinar will feature clinical trial site leaders and R&D executives, who will pass along the latest strategies for boosting site and patient enrollment in phase 1 trials. They will discuss best practices for communicating with both investigators and patients. Register Now! |
Resources Sponsored by: Cambrex The highest number of NCEs approved by the FDA…the fastest growing small molecule clinical pipeline reported in 20 years…these are exciting times for our industry. Sponsored by: Reprints Desk, Inc. Cut your research time in half - with an easy-to-use app for scientists that combines full-featured reference management with integrated search and on-demand document delivery. Sponsored by: Almac Group Innovative Just in Time Manufacturing solution enables sponsors full late stage customisation of clinical trial materials Sponsored by: PwC How are employer activism strategies beginning to replace the cost-sharing of the past, and improve the health of the workforce? Sponsored by: United Cargo and SAVSU Technologies The combination of SAVSU technology with United Airlines’ global network has made it easier than ever to bring cell and gene therapies to destinations beyond major markets. Sponsored by: XiltriX North America Find out in this article how your pharmaceutical organization can leverage IoT technologies and informatics integration to innovate and improve overall operational efficiencies. Sponsored by: Patheon, by Thermo Fisher Scientific When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need. Learn more here. Sponsored by: Veradigm Patient demand for more information on their care is driving new e-prescribing regulations, and technology is evolving to help providers meet them. This report provides an overview of key areas where such regulation has emerged, and what it could mean for providers and healthcare IT companies. Sponsored by: Patheon, by Thermo Fisher Scientific Anticipate challenges in formulation early. Sponsored by: Titian Software This Essential Guide to Managing Laboratory Samples is a three-part piece exploring common problems experienced in the management of samples and how, for any scale of operation, significant efficiency and accuracy benefits can be gained using dedicated sample management software. Sponsored by: Veradigm Patients living with diabetes deserve better – Real-World Evidence for effecting/realizing change in the management of type 2 diabetes and cardiovascular/renal comorbidities. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Latin America Healthcare Compliance Certificate Program September 23-26, 2019 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register NOW and start Pre-Boot Camp Preparation! | 